Altro Health

• Organizations that require enterprise-grade security documentation such as SOC 2 Type II, ISO 27001 certification, a public trust center, penetration testing summaries, or detailed security architecture documentation should note that such documentation was not publicly available for Altro Health in sources reviewed.

• Organizations that require full public disclosure of medication pricing and named pharmacy sourcing for consumer-facing marketing may find Altro’s public materials and ecosystem norms (pricing often disclosed during intake and pharmacies described generically) to be a mismatch.

• Organizations aiming to build a clinical operation under their own legal entity and to exercise primary control over prescribing protocols, clinical staffing, and medical operations may prefer alternatives that enable direct clinical ownership rather than a platform-mediated clinical network.

• Organizations whose growth model depends primarily on paid digital advertising at scale should consider whether additional compliance and certification support (e.g., LegitScript or other advertising readiness services) is required; Altro’s public materials do not clearly document end-to-end advertising compliance and certification services.

• Organizations requiring extensive integration capabilities (deep CRM/EHR integrations, API-first extensibility, data warehouse exports, or extensive BI/reporting) should note that public documentation does not show broad integration or API capabilities.

• Security/compliance documentation gaps (public-facing)

  • No public evidence of SOC 2, ISO 27001, or similar security certifications was found in the sources reviewed.

• HIPAA role ambiguity risk

  • Altro provides HIPAA authorization flows and references BAAs, but the End User Terms emphasize Altro is not automatically a HIPAA covered entity or business associate in some contexts. Buyers should obtain BAAs and clear contractual definitions of PHI flows.

• Third-party medical group dependency

  • Care delivery is facilitated via third-party clinical entities named in the End User Terms; this introduces dependency on partner clinical groups and potential variability in the patient experience.

• Product roadmap and disclosure

  • No public product roadmap with dates or public timelines was identified in the sources reviewed.

• Review scarcity on mainstream platforms

  • Limited presence on major SaaS review platforms reduces the availability of independently authored evaluations of support quality and platform reliability.

• Features and vendor-cited advantages:

  • Pre-built storefront and patient portal designed for co-branding or white-label use, intended to shorten setup time according to vendor statements.
  • Published subscription pricing tiers that target small and mid-sized wellness operators.
  • Pricing controls that the vendor states allow partners to set their own prices for offerings.
  • Vendor claims of nationwide availability across 50 states (buyers should validate state-specific exclusions for particular therapies).

• Competitor advantages to consider:

  • Some competitors publish stronger compliance and security documentation and provide more explicit clinical ownership models or different unit economics (e.g., consult-based fees vs. spreads on medications).

Note: Altro Health does not appear to have broad coverage on mainstream B2B SaaS review platforms (G2/TrustRadius/Capterra/Gartner Peer Insights) under the “Altro Health” listing name in accessible searches. Most publicly available endorsements are vendor-published testimonials or third-party ecosystem writeups referencing brands that route clinical infrastructure through Altro.

• Vendor-published testimonials (marketing content, not independently verified)

  • The vendor site includes testimonials such as:
    • “I switched to Altro from another platform after months wasted integrating… Altro is preconfigured and ready to deploy.” (identified on the vendor page as a named operator)
    • “I was so skeptical at first… impressed! So easy and so reliable.” (identified on the vendor page as a named operator)
  • These testimonials indicate operator claims around perceived ease of setup and reliability, but they are vendor-controlled and not independently verified in the sources reviewed.

• Independent/third-party commentary that functions like reviews (mixed / critical themes)

  • Several third-party writeups about brands using Altro as the underlying checkout system highlight price opacity and checkout flows that disclose pricing only after intake or when entering the vendor-hosted checkout.
  • Another recurring critique in ecosystem discussions is that pharmacy partners are often described generically (e.g., 503A/503B) without named facilities, which reduces sourcing transparency for end users.

• Mainstream review platforms

  • Searches on major SaaS review platforms did not surface a clearly identifiable Altro Health product listing in accessible results; results returned similarly named but unrelated products.

• Why customers reportedly chose the platform (vendor and third-party indications)

  • Vendor claims very rapid setup timelines (vendor assertion: setup may be completed in a short timeframe).
  • Preservation of the operator’s customer relationship: the vendor describes the operational model such that the operator retains direct customer engagement rather than the vendor operating as a direct-to-consumer brand.
  • White-label/co-branded commerce, portal, and payment processing features.
  • Vendor-published claims of nationwide coverage.

• Why some customers may leave / churn risk factors (inferred from ecosystem critiques)

  • Desire for greater operational ownership of clinical services (operators seeking to operate a clinic under their own entity rather than using a mediated model)
  • Need for more transparency on pricing and named pharmacy sourcing
  • Potential scaling constraints related to pricing tiers or hidden unit economics
  • Advertising and compliance friction for paid acquisition channels (operators depending on large-scale paid ads may require additional compliance support)

• Vendor-style case studies

  • The vendor site contains testimonials and summary claims about operator outcomes (e.g., business growth, ease of setup), but detailed case studies with baselines, methodology, timelines, and independently verified metrics were not found in the materials reviewed.

• Partner ecosystem “case-like” pages

  • Some wellness brands reference using Altro as a clinical infrastructure layer and describe clinician review of intake prior to prescribing decisions.

• Critical evaluation (methodology gaps)

  • Vendor claims such as several thousand users, rapid setup timelines, and broad national coverage are presented without disclosed methodology or supporting independent documentation in the sources reviewed.
  • Third-party investigative writeups on price disclosure and sourcing provide useful context but are not controlled studies and vary in rigor.

• Company sizes

  • Best fit: small wellness operators through small chains (small staff sizes; potentially larger for multi-location wellness brands), based on the vendor’s published self-serve pricing model and target operator descriptions.

• Industries/verticals

  • Health coaching practices
  • Medspas and aesthetic clinics (particularly those seeking to add weight-management offerings)
  • Wellness centers and longevity clinics without in-house prescriber infrastructure
  • Fitness studios and personal training brands expanding into medically supervised programs
  • Chiropractic offices adding adjunct weight management, hormone, or lab offerings

• Roles/personas

  • Business owner/operator (coach, medspa owner, studio owner)
  • Operations manager or administrator responsible for patient communications and scheduling
  • Marketing manager or agency handling paid acquisition

• Pain points addressed

  • Adding medically supervised weight-management or hormone offerings without building a medical organization
  • Retaining the customer relationship rather than referring clients to external clinics
  • Reducing complexity of multi-state clinician coverage and compliance

• Qualification criteria (good fit)

  • Existing client base with conversion potential to medically supervised add-on programs
  • Willingness to operate within a platform-mediated clinical and pharmacy network model
  • Acceptance of Altro’s legal and compliance structure (contractual authorizations, arbitration clauses, PHI handling language)

• Deal disqualifiers (poor fit)

  • Organizations that require published, independently verified security certifications (SOC 2 / ISO 27001) as a procurement requirement
  • Organizations that require named pharmacy partners and explicit sourcing transparency on public pages
  • Operators intending to operate the clinical entity directly (e.g., friendly PC/MSO structures) rather than as a partner overlay

• What the product does (core value proposition)

  • Altro Health is a B2B platform intended to enable wellness operators (health coaches, med spas, wellness centers, fitness studios, chiropractic offices, etc.) to offer medically supervised programs such as weight management/body composition, hormone health, longevity-related therapies, and lab testing under the operator’s brand, without the operator establishing a medical practice, pharmacy, or lab infrastructure.
  • Altro describes its role as providing technology and coordination services, while medical services are provided by independent licensed providers; Altro states it is not a pharmacy and does not provide direct medical care.
  • Primary productized deliverables described by the vendor include:
    • A co-branded or white-labeled storefront and patient portal
    • Payment processing
    • Functionality that allows partners to set prices for their offerings
    • Access to remote and on-site lab services and (on the Pro tier) additional lab options such as mobile phlebotomy and custom lab panels
    • Clinician oversight and messaging (vendor-level claim)

• Target market and market positioning

  • Target customers are independent owner-operators and small-to-medium businesses in the wellness ecosystem that want to add prescription programs and labs while maintaining the direct customer relationship.
  • Market positioning is described in some investor and third-party commentary as similar to an ecommerce enablement model for clinical services (often summarized informally as a “clinical Shopify” concept for wellness operators seeking a pre-built medically supervised commerce and workflow layer).

• Company background (founding year, HQ, key leadership)

  • Vendor legal entity: Partner Terms identify the company as Lyv Health Inc. dba Altro Health.
  • Geography: the vendor site lists an address in New York, NY.
  • Leadership/founding: third-party investor descriptions indicate Altro Health was founded in 2025 and is based in New York City.
  • Rebrand context: third-party material indicates the company previously used the Lyv Health name and rebranded to Altro Health.

• Funding and growth (investment rounds, acquisitions, estimated customer count/revenue if public)

  • Vendor-published metrics on the website include claims of several thousand users, dozens of products available, and nationwide coverage. These are vendor assertions and were not independently verified in the sources reviewed for this report.
  • Press reporting indicates Altro Health completed a seed funding round as of the report date; specific amounts and investor names reported in press have been redacted in this public summary.
  • Note: independent validation of user counts, active customer numbers, or revenue was limited in public materials accessible for this research.

• Pricing model with specific tiers and costs where available

  • Starter
    • Published starter tier with monthly billing; vendor also lists a discounted quarterly billing option (vendor describes the quarterly option as a discount).
    • Includes co-branded storefront and patient portal, product catalog, remote and on-site lab access, and partner-controlled pricing.
  • Pro
    • Published pro tier with monthly billing; vendor also lists a discounted quarterly billing option (vendor describes the quarterly option as a discount).
    • Adds white-label storefront (custom domain/branding), basic marketing tools (coupons, Meta Pixel integration), additional lab options (mobile phlebotomy, custom panels), and priority support.
  • Vendor statements indicate no onboarding fees, no long-term contracts, and cancel-anytime policies.

• Total cost of ownership (TCO) considerations

  • The direct platform subscription fees are published (tiered starter/pro pricing with monthly and discounted quarterly billing).
  • Additional costs that are not transparently published and could materially affect TCO include:
    • Patient-facing prices for consults, prescriptions/medications, and lab work and whether the vendor or its partners apply markups
    • Marketing costs (advertising, creative production, compliance-driven landing page adjustments)
    • Legal and compliance expenses for the wellness partner (policy drafting, disclosures, state-specific requirements)
    • Potential certification or advertising compliance costs (e.g., obtaining platform certifications such as LegitScript), if required and the partner is responsible

• Key competitors in the space (direct alternatives)

  • Cuvo Health (white-label telehealth clinic infrastructure)
  • Tessic Health (telehealth platform for medspas; competitor comparison pages reference Altro)
  • Karpa Health (telehealth/wellness program platform; competitor content references Altro)
  • Wheel (enterprise telehealth clinician network/platform; compared in white-label telehealth contexts)
  • Qualiphy (telehealth clinical network/infrastructure)
  • OpenLoop (telehealth enabling; appears in Altro’s terms as a medical group affiliate relationship)